Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Cash & Equivalents (2020 - 2022)

Historic Cash & Equivalents for Atea Pharmaceuticals (AVIR) over the last 3 years, with Q3 2022 value amounting to $176.4 million.

  • Atea Pharmaceuticals' Cash & Equivalents fell 7899.03% to $176.4 million in Q3 2022 from the same period last year, while for Sep 2022 it was $176.4 million, marking a year-over-year decrease of 7899.03%. This contributed to the annual value of $764.4 million for FY2021, which is 1008.59% down from last year.
  • Atea Pharmaceuticals' Cash & Equivalents amounted to $176.4 million in Q3 2022, which was down 7899.03% from $684.5 million recorded in Q2 2022.
  • In the past 5 years, Atea Pharmaceuticals' Cash & Equivalents ranged from a high of $850.1 million in Q4 2020 and a low of $17.1 million during Q1 2020
  • Its 3-year average for Cash & Equivalents is $537.2 million, with a median of $705.5 million in 2022.
  • As far as peak fluctuations go, Atea Pharmaceuticals' Cash & Equivalents soared by 476237.24% in 2021, and later plummeted by 7899.03% in 2022.
  • Over the past 3 years, Atea Pharmaceuticals' Cash & Equivalents (Quarter) stood at $850.1 million in 2020, then dropped by 10.09% to $764.4 million in 2021, then tumbled by 76.92% to $176.4 million in 2022.
  • Its Cash & Equivalents was $176.4 million in Q3 2022, compared to $684.5 million in Q2 2022 and $705.5 million in Q1 2022.